首页> ESMO real world data and digital oncology> Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019.

Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019.

导出 LinkOut

翻译打印收藏纠错

第一作者： L,Moscetti

第一单位： Division of Medical Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.;Gruppo Oncologico Italiano per la Ricerca Clinica (GOIRC), Parma, Italy.

作者： L,Moscetti ^[1] ; E,Barbieri ^[1] ; E,Zattarin ^[2] ; P,Vici ^[3] ; G,Zoppoli ^[4] ; A,Musolino ^[5] ; S,Natalizio ^[6] ; F,Canino ^[7] ; F,Ravera ^[8] ; L,Filomeno ^[3] ; T,Arcuri ^[3] ; C,Omarini ^[1] ; F,Piacentini ^[7] ; M,Barbolini ^[6] ; L,Cortesi ^[1] ; F,Caggia ^[7] ; M,Civallero ^[9] ; M,Dominici ^[2] ; A,Toss ^[2]

作者单位： Division of Medical Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.;Gruppo Oncologico Italiano per la Ricerca Clinica (GOIRC), Parma, Italy. ^[1] Division of Medical Oncology, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, Modena, Italy.;Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy. ^[2] UOSD Sperimentazioni di Fase IV, IRCCS Istituto Nazionale Tumori Regina Elena, Rome, Italy.;Phase IV Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. ^[3] Gruppo Oncologico Italiano per la Ricerca Clinica (GOIRC), Parma, Italy.;IRCCS Policlinico San Martino & Università degli Studi di Genova, Genoa, Italy. ^[4] IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.;Gruppo Oncologico Italiano per la Ricerca Clinica (GOIRC), Parma, Italy. ^[5] Division of Medical Oncology, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, Modena, Italy. ^[6] Gruppo Oncologico Italiano per la Ricerca Clinica (GOIRC), Parma, Italy.;Division of Medical Oncology, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, Modena, Italy. ^[7] IRCCS Policlinico San Martino & Università degli Studi di Genova, Genoa, Italy. ^[8] Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.;Division of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery Oncology and Regenerative Medicine, University Hospital of Modena, Modena, Italy. ^[9]

关键词 abemaciclib breast cancer cyclin 4/6 inhibitors palbociclib ribociclib subsequent treatments

DOI 10.1016/j.esmorw.2025.100154

PMID 41647714

发布时间 2026-02-08

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

ESMO real world data and digital oncology

2025年8卷

100154页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

ESMO real world data and digital oncology

2025年8卷

100154页

检索历史清除

Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019.

ESMO real world data and digital oncology

相似文献

同项目论文

ESMO real world data and digital oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019.

ESMO real world data and digital oncology

相似文献

同项目论文

ESMO real world data and digital oncology

相关期刊

检索历史清除